Overview

For well-positioned companies, the pharmaceutical market in China presents an attractive and rapidly growing opportunity, which is driven by a number of positive trends. These positive trends include strong per capita GDP growth, significantly increased government-backed healthcare reimbursement systems, the massive size and growth of the country’s aging population, and the current fragmented nature of the industry.

China Pharmaceuticals, Inc. (CFMI) is strongly positioned to capitalize on the current opportunities in the pharmaceuticals market in China, particularly as consolidation in this fragmented industry continues to fuel a growing sector for mergers and acquisitions. We are employing a strategy designed to grow our company aggressively through mergers, joint-ventures, and acquisitions, targeting state-owned-enterprise pharmaceutical companies and private pharmaceutical companies with outstanding potential.

For the twelve months period ended December 31, 2010, CFMI recorded total sales revenue of $34,184,906, representing a 28% increase over the same period in 2009. Net income for the twelve months period was $8,409,158. As at December 31, 2010, total shareholders’ equity was $42,532,875 and total assets were $44,777,829.

_____________________________________________________________________

“ In China, we have companies with 30% or more growth rates, and trading for P/E ratios of less than 8, while in the U.S. we have companies with 0% to 5% growth rates trading at P/E ratios of 13 to 16. The Chinese companies clearly present better value for the intelligent investor. ”

Quote from Zack Buckley, Chinese Pharma Stocks Shine TheStreet